2024 CUDA丨Dr. Xiangjun Lyu: Addressing Incontinence Early, Enhancing Pelvic Floor Disease Outcomes with Robotic Surgery

2024 CUDA丨Dr. Xiangjun Lyu: Addressing Incontinence Early, Enhancing Pelvic Floor Disease Outcomes with Robotic Surgery

The 2024 Annual Meeting of the Urological Surgeons Branch of the Chinese Medical Association (CUDA) was held in Xi'an from August 8 to 11, 2024. The conference was hosted by the Chinese Medical Association and the CUDA Urological Surgeons Branch, with the Air Force Medical University Xijing Hospital serving as the organizer and the Shaanxi Provincial Medical Association Urological Surgeons Branch as a co-organizer. Under the theme "Healthy China, Urology First," the conference showcased the latest achievements in urology. At the event, Dr. Xiangjun Lyu from the Chinese PLA General Hospital spoke with Urology Frontier about the importance of correcting patient perceptions regarding urinary incontinence and pelvic floor diseases, emphasizing the benefits of early diagnosis and intervention. She also discussed the role of robotic surgery in improving treatment outcomes for these conditions and its future prospects.
Cutting-edge Bi-monthly: July Literature Digest (Part 1)

Cutting-edge Bi-monthly: July Literature Digest (Part 1)

In this era of information explosion, how can one quickly access the latest developments in the field? Here, we select the latest literature in the field every month, focusing on hot topics, comprehensively interpreting new advances in hematologic diseases, and helping you stay at the forefront of the disease field. Let's track the latest trends together, gain insights into research trends, and explore the boundless possibilities in the world of hematology! Stay tuned every month for the latest updates!
Conference Preview: The 11th Sino-French Hematology Summit of the Chinese Medical Doctor Association will be held in Tianjin in mid-September

Conference Preview: The 11th Sino-French Hematology Summit of the Chinese Medical Doctor Association will be held in Tianjin in mid-September

The "11th Sino-French Hematology Summit of the Chinese Medical Doctor Association," organized by the Chinese Medical Doctor Association, the Hematology Branch of the Chinese Medical Doctor Association, and the French Hematology Association, and hosted by the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences) and the National Clinical Research Center for Hematological Diseases—Peking University Hematology Institute, with the support of the French Bo Xiao Foundation under the French Fund General Assembly, is scheduled to be held in Tianjin from September 13 to 15, 2024. The conference theme focuses on "New Advances in the Treatment of Hematological Malignancies," delving into the latest clinical diagnosis and treatment progress, current hot topics, and core challenges in clinical practice related to the hematopoietic system. This conference sincerely invites authoritative experts in the field of hematology from both international and domestic circles to share their insights and experiences. It is planned to invite 150 hematologists from across the country to participate and exchange academic experiences. We warmly welcome clinicians on the front line of hematology to actively participate in the meeting and jointly promote progress in the field of hematological malignancy treatment.
News Express | Blossoms on the Path to Cancer Cure: The Remarkable Journey of Vinca Alkaloids

News Express | Blossoms on the Path to Cancer Cure: The Remarkable Journey of Vinca Alkaloids

The "News Express" column serves as a bridge between cutting-edge research and clinical practice, enabling hematology enthusiasts and professionals to swiftly capture industry dynamics, ignite innovative thinking, and broaden their professional perspectives. Hematology Frontier carefully selects the latest hematological research findings from top global journals. Each article is a brilliant spark of science and clinical practice, delivering the latest advancements in hematology directly to you. Let knowledge know no boundaries, and let exploration never cease. We invite you to follow the column and join global hematology experts on a journey of scientific discovery! This issue features a review article from Pediatric Blood & Cancer on the role of Vinca alkaloids, a must-read.
Dr. Jian Hou: Treatment of Multiple Myeloma – Coexisting Challenges and Opportunities | The 8th CSCO Hematology Academic Conference

Dr. Jian Hou: Treatment of Multiple Myeloma – Coexisting Challenges and Opportunities | The 8th CSCO Hematology Academic Conference

The 8th Hematology Academic Conference, organized by the Chinese Society of Clinical Oncology (CSCO), CSCO Leukemia Expert Committee, and CSCO Lymphoma Expert Committee, and co-hosted by Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was grandly held in Harbin from July 26 to 28, 2024. On this occasion, "Oncology Frontier - Hematology Frontier" invited Dr. Jian Hou from Renji Hospital of Shanghai JiaoTong University School of Medicine, to share insights on the current status, challenges, and future treatment modes of multiple myeloma (MM).
ASCO 2024 | PostMONARCH Primary Outcomes Released: Abemaciclib + Fulvestrant Continues to Benefit CDK4/6-Pretreated HR+/HER2- Advanced Breast Cancer

ASCO 2024 | PostMONARCH Primary Outcomes Released: Abemaciclib + Fulvestrant Continues to Benefit CDK4/6-Pretreated HR+/HER2- Advanced Breast Cancer

PostMONARCH is the first randomized, placebo-controlled phase III study of its kind. At the 2024 ASCO conference, Dr. Kevin Kalinsky from the Winship Cancer Institute of Emory University presented the primary outcomes of the PostMONARCH study, revealing that continued treatment with abemaciclib (Abemaciclib) + fulvestrant benefits patients even after progression on CDK4/6 inhibitor therapy. This article provides a summary of the study's progress for our readers.